Sona Nanotech Advances Cancer Therapy with First Patient Dosing in Feasibility Study

Sona Nanotech has dosed its first patient in an early feasibility study of its Targeted Hyperthermia Therapy (THT) cancer treatment for advanced melanoma. The study aims to assess safety, tolerability, and preliminary efficacy of the therapy. Initial results are expected in summer, with final results in fall. The trial will evaluate the technology's effectiveness and potential advantages over existing immunotherapy approaches.

Sona Nanotech Inc. (OTCQB: SNANF), an oncology-focused life sciences company, has dosed its first patient in an early feasibility study of its Targeted Hyperthermia Therapy (THT) cancer treatment for advanced melanoma. The study, initiated on July 7, 2025, aims to assess the safety, tolerability, and preliminary efficacy of the therapy [1].

The trial is designed to evaluate THT's impact on tumor growth inhibition and immune system engagement with the cancer. Participants are patients with advanced melanoma who have failed to respond to standard of care immunotherapy protocols. The study includes two treatments of THT, one week apart, and is expected to generate initial results this summer, with final results anticipated in the fall [1].

Dr. Carman Giacomantonio, Sona's Chief Medical Officer, commented, "Our unique therapy aims to modify tumors, making them more visible to the immune system with a view to enabling their elimination. This study will provide key insights into the effects of THT in human cancer" [1]. David Regan, CEO of Sona Nanotech, added, "Getting to this first dosing of a patient with our Targeted Hyperthermia Therapy is a significant milestone achieved through years of research and preclinical studies" [1].

The study will also evaluate the technology's ease of setup, administration, reproducibility, resource requirements, and time to administer the treatment. Participants will be assessed for tolerability, adverse events, clinical response, and pathological immune response [1].

Sona Nanotech believes that THT may offer benefits over current standard of care immunotherapy treatments, which have shown limited response rates and can have undesirable side effects [1].

References:
[1] https://www.tradingview.com/news/reuters.com,2025-07-07:newsml_NFC6z0SRF:0-first-patient-dosed-in-early-feasibility-study-trial-of-its-cancer-therapy/